Cargando…

Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis

Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common type of chronic liver disease worldwide. From the spectrum of NAFLD, it is nonalcoholic steatohepatitis (NASH) that predominantly predisposes patients to higher risk for development of cirrhosis and hepatocellular carcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sayiner, Mehmet, Lam, Brian, Golabi, Pegah, Younossi, Zobair M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243399/ https://www.ncbi.nlm.nih.gov/pubmed/30479664 http://dx.doi.org/10.1177/1756284818811508

Ejemplares similares

Nonalcoholic steatohepatitis: global impact and clinical consequences
por: Kabarra, Khaled, et al.
Publicado: (2021)

Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease
por: Golabi, Pegah, et al.
Publicado: (2019)

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
por: Younossi, Zobair M., et al.
Publicado: (2023)

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis
por: Sayiner, Mehmet, et al.
Publicado: (2017)

Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease
por: Younossi, Zobair M., et al.
Publicado: (2021)

Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease
por: Alqahtani, Saleh A., et al.
Publicado: (2021)

Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States
por: Shahab, Omer, et al.
Publicado: (2019)

Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities
por: Golabi, Pegah, et al.
Publicado: (2017)

Prevalence of Nonalcoholic Fatty Liver Disease in the Female Population
por: Arshad, Tamoore, et al.
Publicado: (2018)

Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes
por: Younossi, Zobair M, et al.
Publicado: (2020)

Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL)
por: Golabi, Pegah, et al.
Publicado: (2016)

The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007‐2017
por: Paik, James M., et al.
Publicado: (2020)

Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016
por: Golabi, Pegah, et al.
Publicado: (2018)

Pediatric Non-Alcoholic Fatty Liver Disease
por: Bush, Haley, et al.
Publicado: (2017)

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
por: Younossi, Zobair M., et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease and Alcoholic Liver Disease are Major Drivers of Liver Mortality in the United States
por: Paik, James M., et al.
Publicado: (2020)

Patients With Lean Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a Higher Risk for Mortality
por: Golabi, Pegah, et al.
Publicado: (2019)

Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006–2016
por: Paik, James M, et al.
Publicado: (2020)

Interrelationship between physical activity and depression in nonalcoholic fatty liver disease
por: Weinstein, Ali A, et al.
Publicado: (2022)

Exercise as an intervention for patients with end-stage liver disease: Systematic review
por: Locklear, Cameron T., et al.
Publicado: (2018)

Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis
por: Jacobson, Ira M., et al.
Publicado: (2022)

Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities
por: Golabi, Pegah, et al.
Publicado: (2020)

The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007‐2017
por: Paik, James M., et al.
Publicado: (2021)

Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis
por: Sinakos, Emmanouil, et al.
Publicado: (2022)

Management of nonalcoholic fatty liver disease in the Middle East
por: Sanai, Faisal M, et al.
Publicado: (2020)

Increasing metabolic co-morbidities are associated with higher risk of advanced fibrosis in nonalcoholic steatohepatitis
por: Wong, Robert J., et al.
Publicado: (2019)

Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality
por: Shahab, Omer, et al.
Publicado: (2018)

Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States
por: Golabi, Pegah, et al.
Publicado: (2019)

Challenges and opportunities in nonalcoholic steatohepatitis
por: Wang, Xiaobo
Publicado: (2022)

The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)
por: Golabi, Pegah, et al.
Publicado: (2016)

Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States
por: Golabi, Pegah, et al.
Publicado: (2016)

Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
por: Mueller, Jessica L, et al.
Publicado: (2015)

Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis‐4 Score
por: Gordon, Stuart C., et al.
Publicado: (2020)

Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease
por: Golabi, Pegah, et al.
Publicado: (2020)

Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD
por: Pearce, Steven G, et al.
Publicado: (2013)

Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients
por: Stepanova, Maria, et al.
Publicado: (2022)

Sarcopenia, healthy living, and mortality in patients with chronic liver diseases
por: Van Dongen, Catherine, et al.
Publicado: (2022)

Polymorphisms in the receptor for advanced glycation end-products (RAGE) gene and circulating RAGE levels as a susceptibility factor for non-alcoholic steatohepatitis (NASH)
por: Mehta, Rohini, et al.
Publicado: (2018)

Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma
por: Sircana, Antonio, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_an4onsbect96rk1lu9ei4teikl